While our community has cheered big breakthroughs when other diseases found their miracle cures, we have waited. There were no new drugs approved for MPN in 2017. No blockbuster scientific breakthroughs.
It can be disheartening or discouraging to wonder when our big break will come.
But we do have hope and optimism because we are investing in MPN research today that will pay off for people living with these rare cancers.
Every day, our staff, board and scientific advisers wake up with a sense of purpose and commitment to make life better for people living with PV, ET and MF. This is the motivation and goal that keeps us going. Here's to what we hope will be a positive new year for people living with and caring for MPN patients everywhere.
PATIENT EDUCATION AND EVENTS
MPN Advocacy and Education International's list of MPN events for 2018
The list of cities includes San Antonio, Chicago, Nashville and more. This is a chance to hear directly from MPN specialists on issues you care about.
Click here for the complete list.
MPN Researchers discuss the news from ASH on video
Drs. Angela Fleischman and John Crispino address questions stemming from the research news from the American Society of Hematology. Click here to watch now.
MPN Clinical trials now recruiting!
Enrolling: MF patients who have been
on a stable dose of Ruxolitinib
Study name: A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis